ReviewPharmaceuticals (Basel, Switzerland)2026
False Novelty in Antibacterial Natural-Product Discovery: Rediscovery, Structural Misassignment, and a Checkpoint Framework for Early Verification.
Review in Pharmaceuticals (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial resistance is outpacing antibacterial innovation, yet most explanations for the shrinking pipeline emphasize downstream economic and regulatory attrition. This review identifies an underexamined upstream bottleneck: the unreliable recognition of genuine chemical novelty when a natural-product hit is first encountered. It advances a unifying framework-false novelty-that treats two conventionally separate failures-the rediscovery of known metabolites and the structural misassignment of genuinely new ones-as coordinate manifestations of a single diagnostic failure, an integration rarely made explicit. Eleven independently verified cases from 2019 to 2025, spanning three rediscoveries and eight misassignments, demonstrate that both failures persist under modern instrumentation. Their persistence, therefore, appears to reflect inconsistent workflow adoption more than a lack of technical capability, since dereplication and computational structure-verification tools mature enough to intercept both are already available. The review translates this diagnosis into a resource-conscious, three-checkpoint verification workflow that matches each failure mode to an appropriate remedy at the discovery stage, where correction is cheapest. Recognizing novelty earlier offers a tractable route to conserving scarce discovery-stage resources.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.